Abstract: Method of treating glaucoma in a mammal, comprising administering to the mammal an effective amount of an active water-soluble carbonic anhydrase inhibitor having the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is selected from the group consisting of H, --OH, --CN and --OCH.sub.3, R.sup.2 is methyl or a lower alkyl having from two to about 5 carbon atoms, R.sup.3 is selected from the group consisting of NHCHR.sup.4 --, R.sup.5 NHCHR.sup.4 --, R.sup.5 NHCHR.sup.4 --, ##STR2## R.sup.4 is selected from lower alkyl having from one to about five carbon atoms, or a naturally occurring amino acid side-chain, and R.sup.5 is selected from the group consisting of H, CH.sub.3 --, HCO--, CH.sub.3 CO-- and X--CH.sub.2 CO-- wherein X is a halogen atom and stereoisomers thereof.

Abstract: Method and formulation useful in treatment of glaucoma in a mammal wherein an effective amount of an active water soluble carbonic anhydrase inhibitor is administered, said inhibitor being a compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is selected from the group consisting of H, NH.sub.2 CH.sub.2 --, --CH(Me)NH.sub.2, --CH(NH.sub.2)CHMe.sub.2, --CH(NH.sub.2)CH.sub.2 CHMe.sub.2, --CH(NH.sub.2)CH(Me)CH.sub.2 Me, 2-pyrrolidinyl residues wherein the R.sup.1 CO-- constitutes an .alpha.-aminoacyl group, N-acetylaminoacyl derivatives and the corresponding dipeptidyl radicals wherein R.sup.1 CO-- is a dipeptidyl residue containing two amino acid residues of the formula where R.sup.1 is --CHR.sup.7 NHCOCHR.sup.8 NH.sub.2, R.sup.6 NHCHR.sup.5 --, ##STR2## and R.sup.6 NHCH.sub.2 CHR.sup.5 --; R.sup.2 is selected from the group consisting of H, alkyl having from 1 to 6 carbon atoms, alkenyl having from 2 to 6 carbon atoms, and cycloalkyl;R.sup.

Abstract: Method and formulation useful in treatment of glaucoma in a mammal wherein an effective amount of an active water soluble carbonic anhydrase inhibitor is administered, said inhibitor being a compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is selected from the group consisting of H, --OH, --CN and --OCH.sub.3 ; R.sup.2 is hydrogen or a lower alkyl having from one to about 5 carbon atoms; R.sup.3 is selected from the group consisting of HNHCHR.sup.4 --, R.sup.5 NHCHR.sup.4 --, R.sup.5 NHCHR.sup.4, CONHCR.sup.4 --, R.sup.5 NHCH.sub.2 CHR.sup.4 --, ##STR2## R.sup.4 is selected from lower alkyl having from one to about 5 carbon atoms; or a naturally occurring amino acid side chain; and R.sub.5 is selected from the group consisting of H, CH.sub.3 --, HCO--, CH.sub.3 CO-- and XCH.sub.2 CO-- wherein X is a halogen atom; and stereoisomers thereof.